{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-005100","form_type":"8-K","ticker":null,"cik":"0001261249","company_name":"AGILE THERAPEUTICS INC","filed_at":"2023-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.155990+00:00","generated_at":"2026-06-17T08:58:05.538757+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Agile Therapeutics receives Nasdaq deficiency notice for negative stockholders' equity","bullets":["Stockholders' equity of -$5.545M as of Dec 31, 2022, below Nasdaq's $2.5M minimum requirement.","Company has until May 11, 2023 to submit a compliance plan to regain listing compliance.","No immediate effect on Nasdaq listing; company intends to submit a plan and consider options.","Alternative compliance standards (market value or net income) also not met."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-005100","json":"https://secwatch.observer/filing/0001558370-23-005100.json","markdown":"https://secwatch.observer/filing/0001558370-23-005100.md","text":"https://secwatch.observer/filing/0001558370-23-005100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1261249/000155837023005100/0001558370-23-005100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1261249/000155837023005100/agrx-20230327x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:58:05.538757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84d46b064863ddf09a9feaaeed56a78d8749cf79","claim":"AGILE THERAPEUTICS INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"(the “Stockholders’ Equity Requirement”). The Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022, reported stockholders’ equity of $(5,545,000), which is below the Stockholders’ Equity Requirement for continued listing on the Nasdaq Capital Market. As of the date of this Current Report on Form 8-K, the Company does not","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1261249/000155837023005100/0001558370-23-005100-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}